Based on their previous study [42], Reinert et al. evaluated the methylation of EOMES, HOXA9, POU4F2, TWIST1, VIM and ZNF154. Their study consisted of a first step, validating the markers and establishing the cut-off levels, and a second step in the surveillance scenario excluding those patients who showed no aberrant methylation of their tumour marker genes. The gene discussed is ZNF154; the disease is neoplasm.